The Pharmaceutical Industry: Key events and trends shaping its current status and future direction

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2006-03-29

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite a tough year in 2005 in terms of the regulatory environment and public opinion, with the withdrawal of Vioxx still at the forefront of peoples' minds, a number of leading pharmas continued to drive impressive growth. Biologicals continued to lead the market in terms of growth with Genentech's cancer focused portfolio driving the fastest growth in 2005 and forecast to do the same in 2006.


Scope

  • Examines the performance of the leading pharma companies in 2005 to reveal the winners and losers by sales growth and share price performance
  • Identifies the products driving market growth and considers the patent expiries that are expected to slow that growth over the coming year
  • Explores the key trends that will shape the pharmaceutical market in 2006 and beyond


    • Report Highlights
    Genentech was the fastest growing of the top 50 pharma and biotech companies in 2005. The company has been one of the major success stories of the last few years, and backs up that reputation with an impressive 46.4% sales growth rate in 2005, building on sales of $3,749m in 2004. Datamonitor also forecasts it to have the fastest growth in 2006.

    2005 was characterized by a lack of mega-mergers between the industry heavyweights, as the major players questioned the value of such huge-scale deals. Nevertheless, it has remained popular to make small, incremental acquisitions to acquire pipeline products or increase presence in specific therapeutic areas a trend expected to continue

    While there were a number of new product launches in 2005, 2006 looks set to see the launch of products with greater potential. Sanofi-Aventis' Acomplia for the treatment of obesity and smoking cessation and Pfizer's inhalable insulin Exubera both have considerable sales potential


    Reasons to Purchase

  • Benchmark the leading companies in terms of sales and share price performance in 2005
  • Uncover the products driving growth in the pharmaceutical industry as well as the key patent expiries likely to restrict it
  • Assess the key trends that will shape the future pharmaceutical market

    • Table of Contents

    Other users found this report page using the following search terms: exubera acomplia genentech companies pharmaceutical 20 top growth sales acquisition merger lipitor ranbaxy

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.